| Characteristic . | Outpatient . | Inpatient . | ICU Survivor . | Death, Nonsurvivor . | Total . |
|---|---|---|---|---|---|
| Subjects | |||||
| No. | 42 | 33 | 57 | 23 | 155 |
| Age, y, mean/median | 69/70 | 69/70 | 67/67 | 70/68 | |
| Male/female | 23/19 | 13/20 | 28/29 | 10/13 | |
| Maximum SOFA scorea | 0 | 2.12 + 3.12 | 5.48 + 3.90 | 6.78 + 3.84 | |
| Median SOFA score | 0 | 1 | 5 | 7 | |
| Serum samples | |||||
| No. | 47 | 45 | 162 | 23 | 277 |
| DFSO = 0–7 | 15 | 14 | 36 | 9 | 74 |
| DFSO = 8–14 | 12 | 7 | 42 | 2 | 63 |
| DFSO > 14 | 17 | 13 | 72 | 12 | 114 |
| UNK | 3 | 11 | 12 | 0 | 26 |
| Characteristic . | Outpatient . | Inpatient . | ICU Survivor . | Death, Nonsurvivor . | Total . |
|---|---|---|---|---|---|
| Subjects | |||||
| No. | 42 | 33 | 57 | 23 | 155 |
| Age, y, mean/median | 69/70 | 69/70 | 67/67 | 70/68 | |
| Male/female | 23/19 | 13/20 | 28/29 | 10/13 | |
| Maximum SOFA scorea | 0 | 2.12 + 3.12 | 5.48 + 3.90 | 6.78 + 3.84 | |
| Median SOFA score | 0 | 1 | 5 | 7 | |
| Serum samples | |||||
| No. | 47 | 45 | 162 | 23 | 277 |
| DFSO = 0–7 | 15 | 14 | 36 | 9 | 74 |
| DFSO = 8–14 | 12 | 7 | 42 | 2 | 63 |
| DFSO > 14 | 17 | 13 | 72 | 12 | 114 |
| UNK | 3 | 11 | 12 | 0 | 26 |
Some COVID-19 cohort subjects had longitude samples. Total No. serum samples = 277.
Abbreviations: COVID-19, coronavirus disease 2019; DFSO, days from symptom onset; ICU, intensive care unit; SOFA, sequential organ failure assessment; UNK, samples without DFSO information.
Mean + standard deviation.
| Characteristic . | Outpatient . | Inpatient . | ICU Survivor . | Death, Nonsurvivor . | Total . |
|---|---|---|---|---|---|
| Subjects | |||||
| No. | 42 | 33 | 57 | 23 | 155 |
| Age, y, mean/median | 69/70 | 69/70 | 67/67 | 70/68 | |
| Male/female | 23/19 | 13/20 | 28/29 | 10/13 | |
| Maximum SOFA scorea | 0 | 2.12 + 3.12 | 5.48 + 3.90 | 6.78 + 3.84 | |
| Median SOFA score | 0 | 1 | 5 | 7 | |
| Serum samples | |||||
| No. | 47 | 45 | 162 | 23 | 277 |
| DFSO = 0–7 | 15 | 14 | 36 | 9 | 74 |
| DFSO = 8–14 | 12 | 7 | 42 | 2 | 63 |
| DFSO > 14 | 17 | 13 | 72 | 12 | 114 |
| UNK | 3 | 11 | 12 | 0 | 26 |
| Characteristic . | Outpatient . | Inpatient . | ICU Survivor . | Death, Nonsurvivor . | Total . |
|---|---|---|---|---|---|
| Subjects | |||||
| No. | 42 | 33 | 57 | 23 | 155 |
| Age, y, mean/median | 69/70 | 69/70 | 67/67 | 70/68 | |
| Male/female | 23/19 | 13/20 | 28/29 | 10/13 | |
| Maximum SOFA scorea | 0 | 2.12 + 3.12 | 5.48 + 3.90 | 6.78 + 3.84 | |
| Median SOFA score | 0 | 1 | 5 | 7 | |
| Serum samples | |||||
| No. | 47 | 45 | 162 | 23 | 277 |
| DFSO = 0–7 | 15 | 14 | 36 | 9 | 74 |
| DFSO = 8–14 | 12 | 7 | 42 | 2 | 63 |
| DFSO > 14 | 17 | 13 | 72 | 12 | 114 |
| UNK | 3 | 11 | 12 | 0 | 26 |
Some COVID-19 cohort subjects had longitude samples. Total No. serum samples = 277.
Abbreviations: COVID-19, coronavirus disease 2019; DFSO, days from symptom onset; ICU, intensive care unit; SOFA, sequential organ failure assessment; UNK, samples without DFSO information.
Mean + standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
